Navigation Links
Verenium Corporation To Announce Second Quarter 2013 Financial Results
Date:7/25/2013

SAN DIEGO, July 25, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release second quarter 2013 financial results on Wednesday, August 7, 2013 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Wednesday, August 7, 2013 at 5:00 p.m. ET.

(Logo:  http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

The call may be accessed by dialing (877) 755-7422 (domestic) or (678) 894-3067 (international) five minutes prior to start time and providing the passcode 19911712.  A link to the live webcast may be accessed by visiting the "Investors" section of the Company's website at http://ir.verenium.com/.  A replay of the event will be available on the Company's website approximately two hours after the call and will be archived for 30 days.

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's estimated revenues, operating loss and capital expenditures for the year ended December 31, 2012, unrestricted cash balance as of Dec
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
2. Verenium To Sponsor And Present At The 2013 Bio World Congress On Industrial Biotechnology
3. Verenium To Introduce New Enzyme Product At 2013 International Fuel Ethanol Workshop & Expo
4. Verenium To Present At Two Upcoming Conferences
5. Verenium Corporation to Announce First Quarter 2013 Financial Results
6. Verenium Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2012
7. Verenium Announces Preliminary Financial Results For Fiscal 2012
8. Verenium To Present At The 25Th Annual Roth Conference
9. Verenium Appoints Holger Liepmann To Its Board Of Directors
10. Verenium To Sponsor The Renewable Fuels Association 18th Annual National Ethanol Conference
11. Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... immune therapies for cancer, announced today that Dr. ... Company, will be making an Industry Expert Theater Presentation ... Chicago on Saturday, May 30, 2015, from ... Theater in McCormick Place. Dr. Bosch will ...
(Date:5/27/2015)... May 27, 2015 The Medical Innovation ... impact of regulation on medical innovation, has been developed ... of Fairleigh Dickinson University’s ( FDU ) Rothman ... Alert pertains to new FDA (Food & Drug ... accelerating the approval of certain medical devices. , ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Innovacyn, ... solutions in the human and animal health industries, ... Vetericyn® Future Innovators of Agriculture College Scholarship Award. ... senior who exhibits a passionate commitment to the ... , This year’s winners, Alexis Pedrow from Anderson ...
(Date:5/26/2015)... 26, 2015  Alere Inc. (NYSE: ALR ) (the ... to timely file its Quarterly Report on Form 10-Q for ... it has received a notice from the New York Stock ... with the NYSE,s continued listing requirements under the timely filing ... Manual. The reason for the delay relates ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3
... Supply Chain Circassia to Develop Dopexamine as Part of ... ... OXFORD, England, October 8 Circassia Ltd, a specialty,biopharmaceutical ... today that it has acquired the US, Canadian and Japanese,development ...
... by allowing for the rapid ... of molecules using a single reaction, ST. LOUIS, ... that it has signed an exclusive licensing,agreement with the ... quantities of powerful new boronic acid,surrogates for use in ...
... for Landmark ApoA-I Trial, TSX Exchange Symbol: ... Corp.,("Resverlogix" or the "Company") (TSX:RVX) is pleased to ... RVX-208 Phase 2b clinical trial,assessing atherosclerosis by IVUS ... Syndrome patients expected to start in 2009., ...
Cached Biology Technology:Circassia Acquires North American and Japanese Rights to Dopexamine 2Circassia Acquires North American and Japanese Rights to Dopexamine 3Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 2Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 3International Steering Committee for RVX-208 IVUS Trial Formed 2International Steering Committee for RVX-208 IVUS Trial Formed 3
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... is available in German . During the ... humans, chromosomes are broken and rearranged at many positions. Using ... Klein, professor for genetics at the Max F. Perutz Laboratories ... high resolution. The surprising observations regarding the mechanism of meiosis ...
... part of human history for well over 30,000 years, used ... paint. Now, researchers from the Perelman School of Medicine ... have a new use for the 21st century: protecting healthy ... In a study just published in BMC Cancer , ...
... Total joint replacement surgeries can help relieve joint ... But sometimes, the debris from prosthetic joints leads ... In 2009, a Wayne State University researcher determined ... treat such disintegration. There was one caveat, however: ...
Cached Biology News:The machinery for recombination is part of the chromosome structure 2The machinery for recombination is part of the chromosome structure 3Penn study shows an ancient crop effective in protecting against a 21st century hazard 2Penn study shows an ancient crop effective in protecting against a 21st century hazard 3Wayne State researcher discovers antibiotic useful for localized treatment of bone wear 2
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
cysteine and glycine-rich protein 2,...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
Biology Products: